# Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer

> **NCT00002662** · PHASE3 · COMPLETED · sponsor: **Aventis Pharmaceuticals**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00002662
- **Lead sponsor:** Aventis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1994-08
- **Primary completion:** —
- **Final completion:** 2004-06
- **Target enrollment:** — (—)
- **Last updated:** 2013-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002662, "Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT00002662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*